Characterization of Pt-, Pd-spermine complexes for their effect on polyamine pathway and cisplatin resistance in A2780 ovarian carcinoma cells

Oncology Reports

Volumn 24, Issue 1, 2010, Pages 15-24

  Tummala, Ramakumar ^a,c   Diegelman, Paula ^a   Fiuza, Sonia M ^b   Batista De Carvalho, Luis A E ^b   Marques, Maria Paula M ^b   Kramer, Debora L ^a   Clark, Kimberly ^a   Vujcic, Slavoljub ^a   Porter, Carl W ^a   Pendyala, Lakshmi ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF COIMBRA   (Portugal)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Cisplatin; Ovarian carcinoma; Polyamine; Spermine complexes

Indexed keywords

ANTINEOPLASTIC AGENT; ARGINASE; ARGINASE 2; CISPLATIN; N1N11 DIETHYLNORSPERMINE; PALLADIUM COMPLEX; PALLADIUM SPERMINE COMPLEX; PLATINUM COMPLEX; PLATINUM SPERMINE COMPLEX; POLYAMINE; POLYAMINE DERIVATIVE; PUTRESCINE; SMOOTHENED PROTEIN; SPERMIDINE; SPERMIDINE DERIVATIVE; SPERMIDINE N1 ACETYL TRANSFERASE; SPERMINE; TRANSCRIPTION FACTOR NRF2; UNCLASSIFIED DRUG; MACROMOLECULE; PALLADIUM; PLATINUM DERIVATIVE;

ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER RESISTANCE; CARCINOMA CELL; CONTROLLED STUDY; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG POTENCY; DRUG POTENTIATION; ENZYME ACTIVATION; ENZYME INDUCTION; FEMALE; GENE EXPRESSION REGULATION; HUMAN; HUMAN CELL; OVARY CARCINOMA; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INDUCTION; PROTEIN SYNTHESIS INHIBITION; SIGNAL TRANSDUCTION; UPREGULATION; CARCINOMA; DNA MICROARRAY; DRUG EFFECTS; DRUG RESISTANCE; DRUG SCREENING; GENE EXPRESSION PROFILING; GENETICS; MACROMOLECULE; METABOLISM; OVARIAN NEOPLASMS; PATHOLOGY; PHARMACOLOGY; TUMOR CELL LINE;

ANTINEOPLASTIC AGENTS; CARCINOMA; CELL LINE, TUMOR; CISPLATIN; DRUG EVALUATION, PRECLINICAL; DRUG RESISTANCE, NEOPLASM; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MACROMOLECULAR SUBSTANCES; METABOLIC NETWORKS AND PATHWAYS; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PALLADIUM; PLATINUM COMPOUNDS; POLYAMINES; SPERMINE;

EID: 77952959761     PISSN: 1021335X     EISSN: 17912431     Source Type: Journal    
DOI: 10.3892/or_00000823     Document Type: Article

References (37)

1. Wang D and Lippard SJ: Cellular processing of platinum anticancer drugs. Nat Rev Drug Discov 4: 307-320, 2005. (Pubitemid 41130944)
2. Andrews PA: Mechanisms of acquired resistance to cisplatin. Cancer Treat Res 73: 217-248, 1994.
3. Rabik CA and Dolan ME: Molecular mechanisms of resistance and toxicity associated with platinating agents. Cancer Treat Rev 33: 9-23, 2007. (Pubitemid 46137553)
4. Gosland M, Lum B, Schimmelpfennig J, Baker J and Doukas M: Insights into mechanisms of cisplatin resistance and potential for its clinical reversal. Pharmacotherapy 16: 16-39, 1996. (Pubitemid 26033168)
5. Siddik ZH: Cisplatin: mode of cytotoxic action and molecular basis of resistance. Oncogene 22: 7265-7279, 2003.
6. Varma R, Hector S, Greco WR, Clark K, Hawthorn L, Porter C and Pendyala L: Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells. Cancer Chemother Pharmacol 59: 711-723, 2007. (Pubitemid 46440593)
7. 1-acetyltransferase. Mol Cancer Ther 3: 813-822, 2004.
8. Tummala R, Porter CW, Diegelman P, Vujcic S, Clark K, Prey J, Kisiel N, Kramer D and Pendyala L: Platinum drug effects on polyamine enzymes in A2780 human ovarian carcinoma cells. Proc Am Assoc Cancer Res 48: Abs 365, 2007.
9. Thomas T and Thomas TJ: Polyamines in cell growth and cell death: molecular mechanisms and therapeutic applications. Cell Mol Life Sci 58: 244-258, 2001. (Pubitemid 32217356)
10. Porter C, Herrera-Omelas L, Pera P, Petrelli NF and Mittleman A: Polyamine biosynthetic activity in normal and neoplastic human colorectal tissues. Cancer 60: 1275-1281, 1987. (Pubitemid 17152906)
11. Leveque J, Foucher F, Bansard JY, Havouis R, Grall JY and Moulinoux JP: Polyamine profiles in tumor, normal tissue of the homologous breast, blood, and urine of breast cancer sufferers. Breast Cancer Res Treat 60: 99-105, 2000. (Pubitemid 30307469)
12. Thomas T, Balabhadrapathruni S, Gallo MA and Thomas TJ: Development of polyamine analogs as cancer therapeutic agents. Oncol Res 13: 123-135, 2002. (Pubitemid 38168454)
13. Creaven PJ, Perez R, Pendyala L, Meropol NJ, Loewen G, Levine E, Berghorn E and Raghavan D: Unusual central nervous system toxicity in a Phase I study of N1N11 diethylnorspermine in patients with advanced malignancy. Invest New Drugs 15: 227-234, 1997. (Pubitemid 27453877)
14. 11-diethylnorspermine (DENSPM) administered TID for 6 days in patients with advanced malignancies. Invest New Drugs 19: 29-39, 2001.
15. 11-diethylnorspermine in patients with non-small cell lung cancer. Clin Cancer Res 8: 684-690, 2002.
16. 11-diethylnorspermine (DENSpm) daily for five days every 21 days in patients with previously treated metastatic breast cancer. Clin Cancer Res 9: 5922-5928, 2001.
17. 11-diethylnorspermine. Cancer Chemother Pharmacol 62: 517-527, 2008.
18. 1-acetyltransferase in determining response to chemotherapeutic agents in colorectal cancer cells. Mol Cancer Ther 6: 128-137, 2007.
19. Ray S, Mohan R, Singh JK, Samantaray MK, Shaikh MM, Panda D and Ghosh P: Anticancer and antimicrobial metallopharmaceutical agents based on palladium, gold, and silver N-heterocyclic carbene complexes. J Am Chem Soc 129: 15042-15053, 2007. (Pubitemid 350237567)
20. Kuduk-Jaworska J, Puszko A, Kubiak M and Pelczynska M: Synthesis, structural, physico-chemical and biological properties of new palladium (II) complexes with 2,6-dimethyl-4-nitropyridine. J Inorg Biochem 98: 1447-1456, 2004. (Pubitemid 38951064)
21. Mansuri-Torshizi H, Ghadimy S and Akbarzadeh N: Synthesis, characterization, DNA binding and cytotoxic studies of platinum (II) and palladium (II) complexes of the 2,2′-bipyridine and an anion of 1,1-cyclobutanedicarboxylic acid. Chem Pharm Bull 49: 1517-1520, 2001. (Pubitemid 33126576)
22. Fiuza SM, Amado PJ, Oliveira VA, Sardao VA, Batista de Carvalho LAE and Marques MPM: Pt (II) vs Pd (II) polyamine complexes as new anticancer drugs: a structure-activity study. Lett Drug Des Discov 3:149-151, 2006.
23. Teixeira LJ, Seabra M, Reis E, da Cruz MT, de Lima MC, Pereira E, Miranda MA and Marques MP: Cytotoxic activity of metal complexes of biogenic polyamines: polynuclear platinum (II) chelates. J Med Chem 47: 2917-2925, 2004. (Pubitemid 38678513)
24. Butour JL, Wimmer S, Wimmer F and Castan P: Palladium(II) compounds with potential antitumour properties and their platinum analogues: a comparative study of the reaction of some orotic acid derivatives with DNA in vitro. Chem Biol Interact 104: 165-178, 1997. (Pubitemid 27263372)
25. Jodrell DI, Evans TR, Steward W, Cameron D, Prendiville J, Aschele C, Noberasco C, Lind M, Carmichael J, Dobbs N, Camboni G, Gatti B and De BF: Phase II studies of BBR3464, a novel tri-nuclear platinum complex, in patients with gastric or gastro-oesophageal adenocarcinoma. Eur J Cancer 40: 1872-1877, 2004.
26. Soares AS, Fiuza SM, Concalves MJ, de Caravalho LAEB, Marques MPM and Urbano AM: Effect of metal center ib tge antitumor activity of the analogous dinuclear spermine chelates (PdCl2)2(spermine) and (PtCl2)2(spermine). Lett Drug Des Discov 4: 460-463, 2007.
27. Varma R, Hector S, Greco WR, Clark K, Hawthorn L, Porter C and Pendyala L: Platinum drug effects on the expression of genes in the polyamine pathway: time-course and concentration-effect analysis based on Affymetrix gene expression profiling of A2780 ovarian carcinoma cells. Cancer Chemother Pharmacol 59: 711-723, 2007. (Pubitemid 46440593)
28. Brun YF, Varma R, Hector SM, Pendyala L, Tummala R and Greco WR: Simultaneous modeling of concentration-effect and time-course patterns in gene expression data from microarrays. Cancer Genomics Proteomics 5: 43-53, 2008. (Pubitemid 351372036)
29. 1-acetyltransferase gene expression. Biochemistry 35: 14436-14444, 1996.
30. 1-acetyltransferase. Mol Pharmacol 64: 1153-1159, 2003.
31. 1-acetyltransferase activity, polyamine pool depletion, and growth inhibition in human melanoma cell lines. Cancer Res 51: 3715-3720, 1991.
32. Bradford MM: A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 52: 5115-5118, 1976.
33. Vujcic S, Halmekyto M, Diegelman P, Gan G, Kramer DL, Janne J and Porter CW: Effects of conditional overexpression of spermidine/spermine N1-acetyltransferase on polyamine pool dynamics, cell growth, and sensitivity to polyamine analogs. J Biol Chem 275: 38319-38328, 2000. (Pubitemid 32009154)
34. Rubinstein LV, Shoemaker RH, Paull KD, et al: Comparison of in vitro anticancer drug screening data generated with a tetrazolium assay versus a protein assay against a diverse panel of human tumor cell lines. J Natl Cancer Inst 82: 1113-1118, 1990.
35. Maxwell P, Longley DB, Latif T, Boyer J, Allen W, Lynch M, McDermott U, Harkin D, Allegra CJ and Johnston PG: Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling. Cancer Res 63: 4602-4606, 2003. (Pubitemid 36951036)
36. Boyer J, Allen WL, McLean EG, Wilson PM, McCulla A, Moore S, Longley DB, Caldas C and Johnston PG: Pharmacogenomic identification of novel determinants of response to chemotherapy in colon cancer. Cancer Res 66: 2765-2777, 2006.
37. 1- acetyltransferase-the turning point in polyamine metabolism. FASEB J 7: 653-661, 1993.